Contineum Therapeutics, Inc. - Common stock (CTNM) analyst actions
Rating and price-target actions on CTNM in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the CTNM overview →
2 measured CTNM analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791 | Press release | +3.04% | -2.40% | |
| Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 | Press release | -1.33% | +3.92% |
Keep exploring
More CTNM: earnings → · SEC filings → · CTNM overview →